Prema Raj Jeyaraj
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Prema Raj Jeyaraj has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Brian Kim Poh Goh
Department of Hepato-pancreato-biliary and Transplant Surgery, Singapore General Hospital, Singapore
8 shared publications - Jin Yao Teo
Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital and National Cancer Centre Singapore, Singapore
6 shared publications - Peng Chung Cheow
Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital and National Cancer Centre Singapore, Academia, 20 College Road, Singapore 169856; Duke-National University of Singapore Medical School, Singapore; Liver Transplant Service, SingHealth Duke-National University of Singapore Transplant Centre, Singapore
6 shared publications - Ye Xin Koh
Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital and National Cancer Centre Singapore, Academia, 20 College Road, Singapore 169856; Duke-National University of Singapore Medical School, Singapore; Liver Transplant Service, SingHealth Duke-National University of Singapore Transplant Centre, Singapore
6 shared publications - Ek Khoon Tan
Department of Hepatopancreatobiliary and Transplant Surgery Singapore General Hospital and National Cancer Centre Singapore Singapore Singapore
5 shared publications - Juinn Huar Kam
Department of General Surgery, Sengkang General Hospital, Singapore
4 shared publications
Latest Publications
- 8 June 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (11) , 2568-2583
Comparative efficacy of advanced preservation strategies for donation after circulatory death liver grafts: A systematic review and network meta-analysis
- 8 June 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (11) , 2568-2583
Comparative efficacy of advanced preservation strategies for donation after circulatory death liver grafts: A systematic review and network meta-analysis
- Open Access
- 26 March 2026
- Published by MDPI AG in Preprints.org
External Validation of The Hospital Frailty Risk Score (HFRS) to Identify Liver Cirrhosis Patients at Risk for Frailty Mortality: A Multi Centre Retrospective Cohort Study in Asians
Background/Objectives: Frailty is a well-established predictor of adverse outcomes in older adults and patients with chronic disease. The Hospital Frailty Risk Score (HFRS), derived from administrative ICD-10 data, was previously developed and validated in Western populations to identify frailty risk. This study aimed to validate the HFRS in an Asian cirrhotic population and evaluate its ability to predict mortality and hospital readmissions. Methods: Patients with liver cirrhosis and at least one hospital admission in 2018 from two tertiary public hospitals in Singapore were identified using ICD-10 codes. HFRS was calculated using a two-year lookback period according to Gilbert’s methodology. Patients were categorized as no risk (score = 0), low risk (score < 5), intermediate risk (5–15), or high risk (>15). Outcomes assessed included 30-day mortality, 30-day hospital readmission, and 2-year mortality, with follow-up until 31 December 2020. Multivariate logistic regression analysis was performed. Results: A total of 814 patients were included, of whom 629 (77.3%) had frailty-related ICD-10 codes. Increasing HFRS category was independently associated with worse outcomes. Compared with the reference group, 30-day mortality increased stepwise with frailty: low risk odds ratio (OR) 25.74 (95% CI 1.54–431.33, p = 0.02), intermediate risk OR 40.42 (95% CI 2.42–676.14, p = 0.01), and high risk OR 50.92 (95% CI 2.92–887.08, p < 0.01). Higher HFRS was also associated with increased 30-day readmission and 2-year mortality across all risk categories. Conclusions: Frailty-related diagnoses are significant independent predictors of mortality and hospital readmission in patients with liver cirrhosis. HFRS is a cost-effective and scalable tool using administrative data to identify high-risk patients and support clinical risk stratification.
- 26 March 2026
- Published by MDPI AG in Preprints.org
Open AccessExternal Validation of The Hospital Frailty Risk Score (HFRS) to Identify Liver Cirrhosis Patients at Risk for Frailty Mortality: A Multi Centre Retrospective Cohort Study in Asians
Background/Objectives: Frailty is a well-established predictor of adverse outcomes in older adults and patients with chronic disease. The Hospital Frailty Risk Score (HFRS), derived from administrative ICD-10 data, was previously developed and validated in Western populations to identify frailty risk. This study aimed to validate the HFRS in an Asian cirrhotic population and evaluate its ability to predict mortality and hospital readmissions. Methods: Patients with liver cirrhosis and at least one hospital admission in 2018 from two tertiary public hospitals in Singapore were identified using ICD-10 codes. HFRS was calculated using a two-year lookback period according to Gilbert’s methodology. Patients were categorized as no risk (score = 0), low risk (score < 5), intermediate risk (5–15), or high risk (>15). Outcomes assessed included 30-day mortality, 30-day hospital readmission, and 2-year mortality, with follow-up until 31 December 2020. Multivariate logistic regression analysis was performed. Results: A total of 814 patients were included, of whom 629 (77.3%) had frailty-related ICD-10 codes. Increasing HFRS category was independently associated with worse outcomes. Compared with the reference group, 30-day mortality increased stepwise with frailty: low risk odds ratio (OR) 25.74 (95% CI 1.54–431.33, p = 0.02), intermediate risk OR 40.42 (95% CI 2.42–676.14, p = 0.01), and high risk OR 50.92 (95% CI 2.92–887.08, p < 0.01). Higher HFRS was also associated with increased 30-day readmission and 2-year mortality across all risk categories. Conclusions: Frailty-related diagnoses are significant independent predictors of mortality and hospital readmission in patients with liver cirrhosis. HFRS is a cost-effective and scalable tool using administrative data to identify high-risk patients and support clinical risk stratification.
- Open Access
- 29 January 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (2)
Hyperammonemia predicts the development of liver-related events in a prospective cohort of stable cirrhosis patients and the external validation of the AMMON-OHE score
Background: Predicting liver-related events (LREs) in stable cirrhosis is crucial; however, traditional scoring methods perform poorly. Ammonia, due to its pathophysiological integration, may prognosticate LRE. This study tests the hypothesis that hyperammonemia can predict LRE and evaluates the AMMON-OHE score in a prospective cohort. Methods: A total of 280 patients with cirrhosis were prospectively enrolled and followed until LRE, liver transplant, or death. Ammonia was measured at enrollment and periodically, along with other parameters. LRE at 1 year was defined as hospitalization for ascites, variceal bleeding, hepatic encephalopathy, or bacterial infection. AMN ≥ULN was calculated by adjusting ammonia to the lab’s upper normal limit. Cox regression and time-dependent analyses were performed. AMMON-OHE was validated using TRIPOD+AI and decision curve analysis. Results: Most patients were male (60.7%), with a mean age of 66.1±10.3 years. MASLD was the commonest etiology (43.7%). Median CTP and MELD scores were 6 (IQR: 5–7) and 8 (IQR: 6–11). Overall, 60 (21.4%) developed LRE at 1 year, and 23 (8.2%) died. In multivariable analysis, AMN ≥ULN was an independent predictor of LRE (HR: 4.92; 95% CI: 2.80–8.64). The AMMON-OHE score predicted LRE with a time-dependent AUROC of 0.859 (CI: 0.810–0.907), outperforming MELD ( p =0.014) but similar to CTP ( p =NS). The AMMON-OHE score underestimated the risk of LRE in our cohort. Conclusions: AMN ≥ULN in stable outpatients with cirrhosis can predict LRE. Although the AMMON-OHE score has a high AUROC, it underestimates the risk of LRE in this cohort.
- 29 January 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (2)
Open AccessHyperammonemia predicts the development of liver-related events in a prospective cohort of stable cirrhosis patients and the external validation of the AMMON-OHE score
Background: Predicting liver-related events (LREs) in stable cirrhosis is crucial; however, traditional scoring methods perform poorly. Ammonia, due to its pathophysiological integration, may prognosticate LRE. This study tests the hypothesis that hyperammonemia can predict LRE and evaluates the AMMON-OHE score in a prospective cohort. Methods: A total of 280 patients with cirrhosis were prospectively enrolled and followed until LRE, liver transplant, or death. Ammonia was measured at enrollment and periodically, along with other parameters. LRE at 1 year was defined as hospitalization for ascites, variceal bleeding, hepatic encephalopathy, or bacterial infection. AMN ≥ULN was calculated by adjusting ammonia to the lab’s upper normal limit. Cox regression and time-dependent analyses were performed. AMMON-OHE was validated using TRIPOD+AI and decision curve analysis. Results: Most patients were male (60.7%), with a mean age of 66.1±10.3 years. MASLD was the commonest etiology (43.7%). Median CTP and MELD scores were 6 (IQR: 5–7) and 8 (IQR: 6–11). Overall, 60 (21.4%) developed LRE at 1 year, and 23 (8.2%) died. In multivariable analysis, AMN ≥ULN was an independent predictor of LRE (HR: 4.92; 95% CI: 2.80–8.64). The AMMON-OHE score predicted LRE with a time-dependent AUROC of 0.859 (CI: 0.810–0.907), outperforming MELD ( p =0.014) but similar to CTP ( p =NS). The AMMON-OHE score underestimated the risk of LRE in our cohort. Conclusions: AMN ≥ULN in stable outpatients with cirrhosis can predict LRE. Although the AMMON-OHE score has a high AUROC, it underestimates the risk of LRE in this cohort.
- Open Access
- 1 April 2025
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 14 (2) , 332-336
Advancing prognostic models in salvage liver transplantation
Advancing prognostic models in salvage liver transplantation
- 1 April 2025
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 14 (2) , 332-336
Open AccessAdvancing prognostic models in salvage liver transplantation
Advancing prognostic models in salvage liver transplantation
- Open Access
- 25 February 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (7)
Atypical memory B cells acquire Breg phenotypes in hepatocellular carcinoma
The functional plasticity of tumor-infiltrating lymphocyte B–cells (TIL-B) spans from antitumor responses to noncanonical immune suppression. Yet, how the tumor microenvironment (TME) influences TIL-B development is still underappreciated. Our current study integrated single-cell transcriptomics and B cell receptor (BCR) sequencing to profile TIL-B phenotypes and clonalities in hepatocellular carcinoma (HCC). Using trajectory and gene regulatory network analysis, we were able to characterize plasma cells and memory and naive B cells within the HCC TME and further revealed a downregulation of BCR signaling genes in plasma cells and a subset of inflammatory TNF + memory B cells. Within the TME, a nonswitched memory B cell subset acquired an age-associated B cell phenotype (TBET + CD11c + ) and expressed higher levels of PD-L1, CD25, and granzyme B. We further demonstrated that the presence of HCC tumor cells could confer suppressive functions on peripheral blood B cells that in turn, dampen T cell costimulation. To the best of our knowledge, these findings represent novel mechanisms of noncanonical immune suppression in HCC. While previous studies identified atypical memory B cells in chronic hepatitis and across several solid cancer types, we further highlighted their potential role as regulatory B cells (Bregs) within both the TME and peripheral blood of HCC patients.
- 25 February 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (7)
Open AccessAtypical memory B cells acquire Breg phenotypes in hepatocellular carcinoma
The functional plasticity of tumor-infiltrating lymphocyte B–cells (TIL-B) spans from antitumor responses to noncanonical immune suppression. Yet, how the tumor microenvironment (TME) influences TIL-B development is still underappreciated. Our current study integrated single-cell transcriptomics and B cell receptor (BCR) sequencing to profile TIL-B phenotypes and clonalities in hepatocellular carcinoma (HCC). Using trajectory and gene regulatory network analysis, we were able to characterize plasma cells and memory and naive B cells within the HCC TME and further revealed a downregulation of BCR signaling genes in plasma cells and a subset of inflammatory TNF + memory B cells. Within the TME, a nonswitched memory B cell subset acquired an age-associated B cell phenotype (TBET + CD11c + ) and expressed higher levels of PD-L1, CD25, and granzyme B. We further demonstrated that the presence of HCC tumor cells could confer suppressive functions on peripheral blood B cells that in turn, dampen T cell costimulation. To the best of our knowledge, these findings represent novel mechanisms of noncanonical immune suppression in HCC. While previous studies identified atypical memory B cells in chronic hepatitis and across several solid cancer types, we further highlighted their potential role as regulatory B cells (Bregs) within both the TME and peripheral blood of HCC patients.
- Open Access
- 6 September 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (11) , 7058-7066
Metroticket approach in a retrospective cohort study to predict overall survival after surgical resection for hepatocellular carcinoma
Background: Surgical resection is a curative therapy for early-stage hepatocellular carcinoma (HCC) patients meeting the Milan criteria as well as a widely used therapy in intermediate-stage HCC. However, intermediate-stage HCC encompasses a wide spectrum of disease and there is a lack of good predictive models for the long-term clinical outcome of HCC patients currently. Here, the authors adopt Mazzaferro’s Metroticket 2.0 to create a robust survival prediction model for intermediate-stage HCC patients undergoing surgical resection. Our algorithm considers age, AFP levels, ALBI score, and nodule size/number to generate survival estimates in an accessible graph format. Importantly, their model surpasses the American Joint Committee on Cancer staging model and was validated with independent US patient data. Methods: The authors conducted a retrospective analysis of OS and RFS in early- and intermediate-stage HCC patients treated with liver resection, including a training cohort in Singapore and a validation cohort in North Carolina, USA. Results: The authors recorded 278 deaths (35.0%) and 428 patients (53.9%) in the first 5 years after surgical resection; higher ALBI score, higher lnAFP, more advanced age and higher tumour burden index were identified as significant parameters. The overall predictive capability of our model, with the inclusion of AFP, is reflected with a UNO’s C-statistic of 0.655, which is 1.11 times better than the 0.5895 C-statistic of the 8th AJCC TNM Staging model. Conclusions: The authors’ modified Metroticket model allows for more granular and better-informed prognostication. This will help surgeons and patients make accurate comparisons between the clinical outcomes of surgical resection and other non-surgical treatments.
- 6 September 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (11) , 7058-7066
Open AccessMetroticket approach in a retrospective cohort study to predict overall survival after surgical resection for hepatocellular carcinoma
Background: Surgical resection is a curative therapy for early-stage hepatocellular carcinoma (HCC) patients meeting the Milan criteria as well as a widely used therapy in intermediate-stage HCC. However, intermediate-stage HCC encompasses a wide spectrum of disease and there is a lack of good predictive models for the long-term clinical outcome of HCC patients currently. Here, the authors adopt Mazzaferro’s Metroticket 2.0 to create a robust survival prediction model for intermediate-stage HCC patients undergoing surgical resection. Our algorithm considers age, AFP levels, ALBI score, and nodule size/number to generate survival estimates in an accessible graph format. Importantly, their model surpasses the American Joint Committee on Cancer staging model and was validated with independent US patient data. Methods: The authors conducted a retrospective analysis of OS and RFS in early- and intermediate-stage HCC patients treated with liver resection, including a training cohort in Singapore and a validation cohort in North Carolina, USA. Results: The authors recorded 278 deaths (35.0%) and 428 patients (53.9%) in the first 5 years after surgical resection; higher ALBI score, higher lnAFP, more advanced age and higher tumour burden index were identified as significant parameters. The overall predictive capability of our model, with the inclusion of AFP, is reflected with a UNO’s C-statistic of 0.655, which is 1.11 times better than the 0.5895 C-statistic of the 8th AJCC TNM Staging model. Conclusions: The authors’ modified Metroticket model allows for more granular and better-informed prognostication. This will help surgeons and patients make accurate comparisons between the clinical outcomes of surgical resection and other non-surgical treatments.
- 1 September 2021
- Published by Elsevier in Surgical Oncology
- Vol. 38, 101586
Time-varying prognostic effects of primary tumor sidedness and grade after curative liver resection for colorectal liver metastases
- 1 September 2021
- Published by Elsevier in Surgical Oncology
- Vol. 38, 101586
Time-varying prognostic effects of primary tumor sidedness and grade after curative liver resection for colorectal liver metastases
- 1 June 2021
- Published by Elsevier in Transplantation Proceedings
- Vol. 53 (5) , 1659-1664
Hepatic Artery Reconstruction in Living Donor Liver Transplantation With the Radial Artery Interpositional Graft
- 1 June 2021
- Published by Elsevier in Transplantation Proceedings
- Vol. 53 (5) , 1659-1664
Hepatic Artery Reconstruction in Living Donor Liver Transplantation With the Radial Artery Interpositional Graft
- Open Access
- 3 May 2021
- Published by Wiley in Cancer Reports
- Vol. 4 (5) , e1393
Resected pancreatic adenocarcinoma: An Asian institution's experience
Background: Pancreatic adenocarcinoma (PDAC) is highly lethal. Surgery offers the only chance of cure, but 5‐year overall survival (OS) after surgical resection and adjuvant therapy remains dismal. Adjuvant trials were mostly conducted in the West enrolling fit patients. Applicability to a general population, especially Asia has not been described adequately.Aim: We aimed to evaluate the clinical outcomes, prognostic factors of survival, pattern, and timing of recurrence after curative resection in an Asian institution.Methods and Results: The clinicopathologic and survival outcomes of 165 PDAC patients who underwent curative resection between 1998 and 2013 were reviewed retrospectively. Median age at surgery was 62.0 years. 55.2% were male, and 73.3% had tumors involving the head of pancreas. The median OS of the entire cohort was 19.7 months. Median OS of patients who received adjuvant chemotherapy was 23.8 months. Negative predictors of survival include lymph node ratio (LNR) of >0.3 (HR = 3.36, P = .001), tumor site involving the body or tail of pancreas (HR = 1.59, P = .046), presence of perineural invasion (PNI) (HR = 2.36, P = .018) and poorly differentiated/undifferentiated tumor grade (HR = 1.86, P = .058). The median time to recurrence was 8.87 months, with 66.1% and 81.2% of patients developing recurrence at 12 months and 24 months respectively. The most common site of recurrence was the liver.Conclusion: The survival of Asian patients with resected PDAC who received adjuvant chemotherapy is comparable to reported randomized trials. Clinical characteristics seem similar to Western patients. Hence, geographical locations may not be a necessary stratification factor in RCTs. Conversely, lymph node ratio and status of PNI ought to be incorporated.
- 3 May 2021
- Published by Wiley in Cancer Reports
- Vol. 4 (5) , e1393
Open AccessResected pancreatic adenocarcinoma: An Asian institution's experience
Background: Pancreatic adenocarcinoma (PDAC) is highly lethal. Surgery offers the only chance of cure, but 5‐year overall survival (OS) after surgical resection and adjuvant therapy remains dismal. Adjuvant trials were mostly conducted in the West enrolling fit patients. Applicability to a general population, especially Asia has not been described adequately.Aim: We aimed to evaluate the clinical outcomes, prognostic factors of survival, pattern, and timing of recurrence after curative resection in an Asian institution.Methods and Results: The clinicopathologic and survival outcomes of 165 PDAC patients who underwent curative resection between 1998 and 2013 were reviewed retrospectively. Median age at surgery was 62.0 years. 55.2% were male, and 73.3% had tumors involving the head of pancreas. The median OS of the entire cohort was 19.7 months. Median OS of patients who received adjuvant chemotherapy was 23.8 months. Negative predictors of survival include lymph node ratio (LNR) of >0.3 (HR = 3.36, P = .001), tumor site involving the body or tail of pancreas (HR = 1.59, P = .046), presence of perineural invasion (PNI) (HR = 2.36, P = .018) and poorly differentiated/undifferentiated tumor grade (HR = 1.86, P = .058). The median time to recurrence was 8.87 months, with 66.1% and 81.2% of patients developing recurrence at 12 months and 24 months respectively. The most common site of recurrence was the liver.Conclusion: The survival of Asian patients with resected PDAC who received adjuvant chemotherapy is comparable to reported randomized trials. Clinical characteristics seem similar to Western patients. Hence, geographical locations may not be a necessary stratification factor in RCTs. Conversely, lymph node ratio and status of PNI ought to be incorporated.